Dr. Rollie Carlson, CEO of Immunexpress discusses the development and commercialization plans for SeptiCyte® RAPID. SeptiCyte® RAPID is a test that quantifies the immune response to infection and will provide actionable results in about one hour to guide physicians when making patient management decisions.
Rolland (Rollie) Carlson, Ph.D. is CEO at Immunexpress, a molecular diagnostic company committed to improving outcomes for patients suspected of sepsis. Dr. Carlson has over 25 years’ experience in business and new product development, global commercial and general management in biotechnology. Previously, he served as President and CEO of WaferGen Biosystems. Prior to WaferGen, Dr. Carlson was President and CEO of Asuragen, a privately-held molecular diagnostic company. Earlier in his career, over a 20-year period, he held increasingly senior positions at Abbott Laboratories, including Vice President and General Manager of the Vysis molecular diagnostic business following its acquisition. Dr. Carlson graduated with Ph.D. in Botany and Plant Physiology from Southern Illinois University and was a post-doctoral research fellow at the Harbor Branch Oceanographic Research Institute in Florida.